Livforsakringsbolaget Skandia Omsesidigt Sells 20,600 Shares of United Therapeutics Corporation $UTHR

Key Points

• Livforsakringsbolaget Skandia Omsesidigt reduced its stake in United Therapeutics Corporation by 98.1%, leaving it with only 400 shares after selling 20,600 shares in the second quarter.
• United Therapeutics reported a quarterly earnings miss with an EPS of $6.41, falling short of the $6.80 consensus estimate, despite a year-over-year revenue growth of 11.7%.
• Analyst ratings for United Therapeutics have been mixed, with target price adjustments ranging from $314.00 to $560.00, reflecting a consensus rating of "Moderate Buy" with an average target price of $438.85.

Livforsakringsbolaget Skandia Omsesidigt lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 98.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 400 shares of the biotechnology company's stock after selling 20,600 shares during the period. Livforsakringsbolaget Skandia Omsesidigt's holdings in United Therapeutics were worth $115,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in UTHR. Focus Partners Wealth increased its position in shares of United Therapeutics by 127.1% during the fourth quarter. Focus Partners Wealth now owns 1,917 shares of the biotechnology company's stock worth $679,000 after acquiring an additional 1,073 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of United Therapeutics by 26.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,446 shares of the biotechnology company's stock worth $2,281,000 after acquiring an additional 1,342 shares in the last quarter. Quantinno Capital Management LP increased its position in shares of United Therapeutics by 76.7% during the fourth quarter. Quantinno Capital Management LP now owns 2,311 shares of the biotechnology company's stock worth $815,000 after acquiring an additional 1,003 shares in the last quarter. Silvercrest Asset Management Group LLC lifted its stake in United Therapeutics by 6.1% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 977 shares of the biotechnology company's stock valued at $345,000 after acquiring an additional 56 shares in the last quarter. Finally, State of Wyoming bought a new stake in United Therapeutics in the 4th quarter valued at approximately $62,000. Institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. UBS Group boosted their target price on United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research note on Thursday, September 4th. Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Cantor Fitzgerald raised their target price on United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a report on Wednesday, September 10th. Bank of America boosted their target price on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company lifted their price target on United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Nine equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $438.85.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded up $6.19 during midday trading on Thursday, hitting $409.87. The company had a trading volume of 851,311 shares, compared to its average volume of 859,121. The stock has a market capitalization of $18.49 billion, a P/E ratio of 16.00, a P/E/G ratio of 6.15 and a beta of 0.62. The company has a 50 day moving average of $327.11 and a 200 day moving average of $309.92. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.85 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Jan Malcolm sold 700 shares of the business's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $400.29, for a total transaction of $280,203.00. Following the completion of the sale, the director directly owned 520 shares in the company, valued at $208,150.80. The trade was a 57.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $400.56, for a total value of $9,012,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 170,316 shares of company stock worth $62,508,783. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.